To view the full story, click the title link.
NYS Entity Status
NYS Filing Date
FEBRUARY 08, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - ELI WASSERMAN INC.
AROUND THE WEB
- Greg David on NY: Why developing in Midtown remains a Herculean task
Monday Jun 19, 2017
- Food & Wine Magazine Will Leave New York for Alabama
By STEPHANIE STROM - Friday Jun 23, 2017
The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.
- Five Sites of New York’s L.G.B.T. History
Monday Jun 19, 2017
Jacob Riis Park, a Manhattan church, the Bum Bum Bar and more. In 360 degrees, visit five sites that helped shape New York City’s L.G.B.T. community and its history.
- Pride 2017: New York’s L.G.B.T.Q. Story Began Well Before Stonewall
By LIAM STACK - Monday Jun 19, 2017
The gay bar’s 1969 patron-police battle, hailed as a starting point, actually followed many events in the city, now mapped in a sites project.
- New York City and James Blake Resolve Excessive-Force Claim
By BENJAMIN MUELLER - Wednesday Jun 21, 2017
As part of the deal with the former pro tennis player, the city will create a new position within the agency that investigates police misconduct.
- Ask the NY Giants: Socks with Sandals?
Tuesday Sep 15, 2015
Professional athletes like members of the New York Giants are the inspiration for the latest (counterintuitive) high-fashion trend: wearing socks with sandals. Photo: Stu Woo/The Wall Street Journal
- Athenex IPO Raises $66M to Fund Clinical Trials for Cancer Drugs
By Frank Vinluan - Wednesday Jun 14, 2017
The IPO window is still open for clinical-stage drug companies, and Athenex is now the latest one to pass through it. The cancer drug developer raised $66 million through a public stock offering on Wednesday, funding that the company will devote mostly to a pair of cancer drugs in late-stage clinical development. Athenex priced its […]
- Teva Seeks to Keep Pace in Migraine Drug Race With Trial Results
By Frank Vinluan - Wednesday May 31, 2017
An experimental Teva Pharmaceutical migraine drug has met the main goals of a late-stage clinical trial, keeping the drugmaker in the race to bring to the market a product that prevents migraine headaches instead of treating them after they start. Teva (NYSE: TEVA) reported Wednesday that its drug fremanezumab reduced the number of days during […]